(Q45036337)

8 December 2017

title

Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis (English)

1 reference

interstitial lung disease

8 December 2017

1 reference

1 reference

6

1 reference

8 December 2017

Tetsuji Sawada

1

1 reference

8 December 2017

Shigeko Inokuma

2

1 reference

8 December 2017

Takeo Sato

3

1 reference

8 December 2017

Takeshi Otsuka

4

1 reference

8 December 2017

Yukihiko Saeki

5

1 reference

8 December 2017

Takemasa Matsuda

7

1 reference

8 December 2017

Tamiko Takemura

8

1 reference

8 December 2017

Akira Sagawa

9

1 reference

8 December 2017

Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology

10

1 reference

8 December 2017

publication date

25 March 2009

1 reference

8 December 2017

1 reference

8 December 2017

volume

48

1 reference

8 December 2017

issue

9

1 reference

8 December 2017

page(s)

1069-1072

1 reference

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Interstitial lung disease associated with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Leflunomide-Induced Pneumonitis in a Patient with Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Genetic analysis of sporadic and familial interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

Risk factors for adverse drug reactions--epidemiological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP052

10.1093/RHEUMATOLOGY/KEP052

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference